Role of B7‐H3 in predicting response to neoadjuvant chemotherapy in muscle‐invasive bladder cancer
Abstract Background Neoadjuvant platinum‐based chemotherapy offers a modest survival advantage in muscle‐invasive bladder cancer (MIBC) for patients with pathologic response. B7‐H3 (CD276), an immune checkpoint overexpressed in various cancers, including urothelial‐cell carcinoma (UCC), has been ass...
Saved in:
Main Authors: | Ekamjit S. Deol, Reza Nabavizadeh, Roxane R. Lavoie, Mihai G. Dumbrava, Edlira Horjeti, Prabin Thapa, John C. Cheville, Igor Frank, Fabrice Lucien |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2024-11-01
|
Series: | BJUI Compass |
Subjects: | |
Online Access: | https://doi.org/10.1002/bco2.418 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Real-world data on utilization of neoadjuvant chemotherapy for muscle invasive bladder cancer: impact on surgical complications and oncological efficacy
by: Hege S. Haugnes, et al.
Published: (2025-01-01) -
Breast Cancer: Neoadjuvant Chemotherapy
by: Barbara F. Shea, et al.
Published: (2015-05-01) -
Breast Cancer: Neoadjuvant Chemotherapy
by: Barbara F. Shea, et al.
Published: (2015-05-01) -
Alterations in DNA Damage Repair Genes Before and After Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer
by: Ursula Lemberger, et al.
Published: (2025-01-01) -
COMBINED TREATMENT OF LOCALLY-ADVANCED BLADDER CANCER
by: I. V. Chernyshev, et al.
Published: (2016-01-01)